

# Dianne Nicol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5531738/publications.pdf>

Version: 2024-02-01

102  
papers

2,164  
citations

279798

23  
h-index

265206

42  
g-index

103  
all docs

103  
docs citations

103  
times ranked

1828  
citing authors

#	ARTICLE	IF	CITATIONS
1	Return of genomic results does not motivate intent to participate in research for all: Perspectives across 22 countries. <i>Genetics in Medicine</i> , 2022, 24, 1120-1129.	2.4	8
2	An ethico-legal assessment of intellectual property rights and their effect on COVID-19 vaccine distribution: an Australian case study. <i>Journal of Law and the Biosciences</i> , 2022, 9, .	1.6	3
3	Identifying the nature and extent of public and donor concern about the commercialisation of biobanks for genomic research. <i>European Journal of Human Genetics</i> , 2021, 29, 503-511.	2.8	10
4	Demonstrating trustworthiness when collecting and sharing genomic data: public views across 22 countries. <i>Genome Medicine</i> , 2021, 13, 92.	8.2	39
5	The Regulatory Role of Patents in Innovative Health Research and Its Translation from the Laboratory to the Clinic. , 2021, , 139-147.		2
6	Bespoke regulation for bespoke medicine? A comparative analysis of bioprinting regulation in Europe, the USA and Australia. <i>Journal of 3D Printing in Medicine</i> , 2021, 5, 155-167.	2.0	6
7	Toward better governance of human genomic data. <i>Nature Genetics</i> , 2021, 53, 2-8.	21.4	31
8	Integrating Public Participation, Transparency and Accountability Into Governance of Marketing Authorisation for Genome Editing Products. <i>Frontiers in Political Science</i> , 2021, 3, .	1.7	4
9	Pathways, Processes and Protections: Australia's Clinical and Direct-to-Consumer Genetic Testing Spaces. <i>Journal of Law &amp; Medicine</i> , 2021, 28, 370-388.	0.0	0
10	Public reactions to direct-to-consumer genetic health tests: A comparison across the US, UK, Japan and Australia. <i>European Journal of Human Genetics</i> , 2020, 28, 339-348.	2.8	8
11	Members of the public in the USA, UK, Canada and Australia expressing genetic exceptionalism say they are more willing to donate genomic data. <i>European Journal of Human Genetics</i> , 2020, 28, 424-434.	2.8	29
12	Regulating innovative health technologies: dialectics, dialogics, and the case of faecal microbiota transplants. <i>Law, Innovation and Technology</i> , 2020, 12, 284-296.	3.2	0
13	Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing. <i>CRISPR Journal</i> , 2020, 3, 332-349.	2.9	15
14	Global citizen deliberation on genome editing. <i>Science</i> , 2020, 369, 1435-1437.	12.6	47
15	Mitochondrial Donation: The Australian Story. <i>Journal of Bioethical Inquiry</i> , 2020, 17, 161-164.	1.5	1
16	Global Public Perceptions of Genomic Data Sharing: What Shapes the Willingness to Donate DNA and Health Data?. <i>American Journal of Human Genetics</i> , 2020, 107, 743-752.	6.2	76
17	A Scenario-Based Methodology for Analyzing the Ethical, Legal, and Social Issues in Genomic Data Sharing. <i>Journal of Empirical Research on Human Research Ethics</i> , 2020, 15, 355-364.	1.3	4
18	The Regulation of Human Germline Genome Modification in Australia. , 2020, , 543-567.		0

#	ARTICLE	IF	CITATIONS
19	Reply to C.D. Richter. <i>European Journal of Human Genetics</i> , 2020, 28, 537-538.	2.8	0
20	Unconventional Practice, "Innovative" Interventions and the National Law. <i>Journal of Law &amp; Medicine</i> , 2020, 27, 574-589.	0.0	1
21	Australian Perspectives on the Ethical and Regulatory Considerations for Responsible Data Sharing in Response to the COVID-19 Pandemic. <i>Journal of Law &amp; Medicine</i> , 2020, 27, 829-838.	0.0	0
22	Don Chalmers: His Contributions to Legal Research and Education, Health Law, and Research Ethics, Locally and Globally. <i>Journal of Law &amp; Medicine</i> , 2020, 28, 289-297.	0.0	0
23	Trust in genomic data sharing among members of the general public in the UK, USA, Canada and Australia. <i>Human Genetics</i> , 2019, 138, 1237-1246.	3.8	69
24	Consent insufficient for data release. <i>Science</i> , 2019, 364, 445-446.	12.6	9
25	The continuing saga of patents and non-invasive prenatal testing. <i>Prenatal Diagnosis</i> , 2019, 39, 441-447.	2.3	5
26	Continental drift? Do European clinical genetic testing laboratories have a patent problem?. <i>European Journal of Human Genetics</i> , 2019, 27, 997-1007.	2.8	8
27	International Divergence in Gene Patenting. <i>Annual Review of Genomics and Human Genetics</i> , 2019, 20, 519-541.	6.2	11
28	Gene Editing Clinical Trials Could Slip through Australian Regulatory Cracks. <i>Journal of Law &amp; Medicine</i> , 2019, 27, 274-283.	0.0	0
29	Terms of Engagement: Transfer of Biological Materials for Research in Australia. <i>Journal of Law &amp; Medicine</i> , 2019, 27, 338-354.	0.0	0
30	Patenting nature—a comparative perspective. <i>Journal of Law and the Biosciences</i> , 2018, 5, 550-589.	1.6	7
31	Australia: regulating genomic data sharing to promote public trust. <i>Human Genetics</i> , 2018, 137, 583-591.	3.8	14
32	Provenance and risk in transfer of biological materials. <i>PLoS Biology</i> , 2018, 16, e2006031.	5.6	7
33	Predicting Public Attitudes Toward Gene Editing of Germlines: The Impact of Moral and Hereditary Concern in Human and Animal Applications. <i>Frontiers in Genetics</i> , 2018, 9, 704.	2.3	38
34	Why We Should Simplify Transfers Of Research Materials. , 2018, , .		0
35	Identifying public expectations of genetic biobanks. <i>Public Understanding of Science</i> , 2017, 26, 671-687.	2.8	25
36	The ethics of genome editing in the clinic: A dose of realism for healthcare leaders. <i>Healthcare Management Forum</i> , 2017, 30, 159-163.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Ethics and Governance of Stem Cell Banks. <i>Methods in Molecular Biology</i> , 2017, 1590, 99-112.	0.9	4
38	Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. <i>Genome Medicine</i> , 2017, 9, 85.	8.2	17
39	Implementing values-based governance for a new bioresource model. <i>Journal of Law and the Biosciences</i> , 2017, 4, 404-411.	1.6	0
40	Understanding public reactions to commercialization of biobanks and use of biobank resources. <i>Social Science and Medicine</i> , 2016, 162, 79-87.	3.8	53
41	Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era. <i>BMC Medical Ethics</i> , 2016, 17, 39.	2.4	81
42	Streamlining ethical review of data intensive research. <i>BMJ</i> , The, 2016, 354, i4181.	6.0	9
43	Compulsory licensing of patents. <i>Information and Communications Technology Law</i> , 2016, 25, 247-271.	1.5	1
44	Precision medicine: drowning in a regulatory soup?. <i>Journal of Law and the Biosciences</i> , 2016, 3, 281-303.	1.6	18
45	Ethics review for international data-intensive research. <i>Science</i> , 2016, 351, 1399-1400.	12.6	44
46	Genomics in research and health care with Aboriginal and Torres Strait Islander peoples. <i>Monash Bioethics Review</i> , 2015, 33, 203-209.	0.8	11
47	Public reaction to direct-to-consumer online genetic tests: Comparing attitudes, trust and intentions across commercial and conventional providers. <i>Public Understanding of Science</i> , 2015, 24, 731-750.	2.8	29
48	Are the gene-patent storm clouds dissipating? A global snapshot. <i>Nature Biotechnology</i> , 2015, 33, 347-352.	17.5	9
49	The Impact of Commercialisation and Genetic Data Sharing Arrangements on Public Trust and the Intention to Participate in Biobank Research. <i>Public Health Genomics</i> , 2015, 18, 160-172.	1.0	60
50	Marking Shifts in Human Research Ethics in the Development of Biobanking. <i>Public Health Ethics</i> , 2015, 8, 63-71.	1.0	16
51	Community Engagement for Big Epidemiology: Deliberative Democracy as a Tool. <i>Journal of Personalized Medicine</i> , 2014, 4, 459-474.	2.5	49
52	To share or not to share is the question. <i>Applied &amp; Translational Genomics</i> , 2014, 3, 116-119.	2.1	9
53	A review of the key issues associated with the commercialization of biobanks. <i>Journal of Law and the Biosciences</i> , 2014, 1, 94-110.	1.6	87
54	A Role for Research Ethics Committees in Exchanges of Human Biospecimens Through Material Transfer Agreements. <i>Journal of Bioethical Inquiry</i> , 2014, 11, 301-306.	1.5	12

#	ARTICLE	IF	CITATIONS
55	New avenues within community engagement: addressing the ingenuity gap in our approach to health research and future provision of health care. <i>Journal of Responsible Innovation</i> , 2014, 1, 321-328.	4.9	12
56	Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. <i>Federal Law Review</i> , 2014, 42, 1-32.	0.4	0
57	Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. <i>Federal Law Review</i> , 2014, 42, 1-32.	0.4	0
58	Patent landscaping for life sciences innovation: toward consistent and transparent practices. <i>Nature Biotechnology</i> , 2013, 31, 202-206.	17.5	42
59	Using TRIPS flexibilities to facilitate access to medicines. <i>Bulletin of the World Health Organization</i> , 2013, 91, 533-539.	3.3	26
60	Direct-to-consumer genetic testing – a regulatory nightmare?. <i>Medical Journal of Australia</i> , 2013, 198, 501-502.	1.7	3
61	Beyond Open Source: Patents, Biobanks and Sharing. , 2013, , 191-208.		5
62	Do patents impede the provision of genetic tests in Australia?. <i>Australian Health Review</i> , 2013, 37, 281.	1.1	6
63	The Regulatory Framework for Protection of Genetic Privacy in Australia. , 2013, , 283-321.		1
64	A Role for Virtual Biotechnology Companies in Drug Discovery and Development?. <i>Journal of Commercial Biotechnology</i> , 2013, 19, .	0.4	1
65	Personalised medicine in the genome era. <i>Journal of Law &amp; Medicine</i> , 2013, 20, 577-94.	0.0	5
66	Body ownership and research. <i>Journal of Law &amp; Medicine</i> , 2013, 21, 323-9.	0.0	2
67	Benefit sharing and biobanking in Australia. <i>Public Understanding of Science</i> , 2012, 21, 534-555.	2.8	43
68	Predicting intention to biobank: a national survey. <i>European Journal of Public Health</i> , 2012, 22, 139-144.	0.3	84
69	Standards for Biobank Access and Intellectual Property. , 2012, , .		3
70	Understanding the impact of commercialization on public support for scientific research: Is it about the funding source or the organization conducting the research?. <i>Public Understanding of Science</i> , 2011, 20, 347-366.	2.8	40
71	Genetic Testing and Protection of Genetic Privacy. , 2011, , 235-255.		1
72	Collaborative Licensing in Biotechnology: A Survey of Knowledge, Experience, and Attitudes in Australia. <i>Biotechnology Law Report</i> , 2010, 29, 465-483.	0.1	1

#	ARTICLE	IF	CITATIONS
73	Strong Patent Rights, Weak Patent Standards and Innovation in Biomedicine. , 2009, , .		1
74	Human genetic databanks in Australia: indications of inconsistency and confusion. <i>New Genetics and Society</i> , 2008, 27, 311-321.	1.2	6
75	Navigating the molecular diagnostic patent landscape. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 461-472.	5.0	4
76	Pharmacogenetic testing: legal considerations for consent, privacy and disclosure. <i>Personalized Medicine</i> , 2008, 5, 155-161.	1.5	8
77	Whither Patent Use without Authorisation in Australia?. <i>Federal Law Review</i> , 2008, 36, 331-362.	0.4	2
78	Whither Patent Use without Authorisation in Australia?. <i>Federal Law Review</i> , 2008, 36, 331-362.	0.4	0
79	Human genetic research databases and biobanks: towards uniform terminology and Australian best practice. <i>Journal of Law &amp; Medicine</i> , 2008, 15, 538-55.	0.0	9
80	Strategies for dissemination of university knowledge. <i>Health Law Journal</i> , 2008, 16, 207-35.	0.2	6
81	Regulatory Capitalism, Business Models and the Knowledge Economy. , 2008, , .		0
82	Gene patentsâ€”more evidence needed, but policymakers must act. <i>Nature Biotechnology</i> , 2007, 25, 388-389.	17.5	6
83	Cooperative Intellectual Property in Biotechnology. <i>Script Ed</i> , 2007, 4, 136-151.	0.8	0
84	Trust, patents and public perceptions: the governance of controversial biotechnology research. <i>Nature Biotechnology</i> , 2006, 24, 1352-1354.	17.5	38
85	Public Trust, Intellectual Property and Human Genetic Databanks: The Need to Take Benefit Sharing Seriously. <i>Journal of International Biotechnology Law</i> , 2006, 3, .	0.1	9
86	Capital, trust & consultation: Databanks and regulation in Australia. <i>Critical Public Health</i> , 2005, 15, 349-358.	2.4	15
87	Balancing Innovation and Access to Healthcare through the Patent System â€” An Australian Perspective. <i>Public Health Genomics</i> , 2005, 8, 228-234.	1.0	6
88	Are patents for methods of medical treatment contrary to the ordre public and morality or "generally inconvenient"?. <i>Journal of Medical Ethics</i> , 2004, 30, 470-475.	1.8	11
89	Commercialisation of biotechnology: public trust and research. <i>International Journal of Biotechnology</i> , 2004, 6, 116.	1.2	31
90	Balancing access to pharmaceuticals with patent rights. <i>Monash Bioethics Review</i> , 2003, 22, S50-S62.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Human gene patents: under whose control?. Medical Journal of Australia, 2003, 179, 181-182.	1.7	0
92	Cell counts and maps in the larval central nervous system of the ascidian <i>Ciona intestinalis</i> (L.). Journal of Comparative Neurology, 1991, 309, 415-429.	1.6	223
93	Development of the central nervous system of the larva of the ascidian, <i>Ciona intestinalis</i> L. Developmental Biology, 1988, 130, 721-736.	2.0	145
94	Development of the central nervous system of the larva of the ascidian, <i>Ciona intestinalis</i> L. Developmental Biology, 1988, 130, 737-766.	2.0	197
95	An analysis of the number and composition of the synaptic populations formed by photoreceptors of the fly. Journal of Comparative Neurology, 1982, 207, 29-44.	1.6	109
96	Regulation in the number of fly photoreceptor synapses: The effects of alterations in the number of presynaptic cells. Journal of Comparative Neurology, 1982, 207, 45-60.	1.6	36
97	The Innovation Pool in Biotechnology: The Role of Patents in Facilitating Innovation. SSRN Electronic Journal, 0, , .	0.4	2
98	Another Missed Opportunity to Reform Compulsory Licensing and Crown Use in Australia. SSRN Electronic Journal, 0, , .	0.4	1
99	Opening the dam: patent pools, innovation and access to essential medicines. , 0, , 235-262.		3
100	Patents and Medical Biotechnology: An Empirical Analysis of Issues Facing the Australian Industry. SSRN Electronic Journal, 0, , .	0.4	13
101	Breast Cancer Gene Research and Medical Practices. , 0, , .		15
102	Submission in Response to the Australian Productivity Commission's Inquiry into IP Arrangements Draft Report. SSRN Electronic Journal, 0, , .	0.4	0